Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Remdesivir Clear all
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 17, 2026, 5:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)

NCT04790240
View directory record Official record
Conditions
Covid19 Virus Infection
Interventions
Inflammation (I), Inflammation (II), Inflammation (III), Standard of care
Dietary Supplement · Drug
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Results available

ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

NCT04583956
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Risankizumab
Other · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
32
States / cities
Tucson, Arizona • Bakersfield, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 17, 2026, 5:27 AM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780424
View directory record Official record
Conditions
COVID-19
Interventions
BRII-196, BRII-198, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
76
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Results available

Impact of Colchicine and Low-dose Naltrexone on COVID-19

NCT04756128
View directory record Official record
Conditions
Covid19
Interventions
Colchicine 0.6 mg, Naltrexone
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

NCT04409262
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
Remdesivir, Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Phoenix, Arizona • Chula Vista, California • Irvine, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780437
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
88
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 17, 2026, 5:27 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

NCT04672564
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Carrimycin, Placebo
Drug
Lead sponsor
Shenyang Tonglian Group CO., Ltd
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Remdesivir in Participants Below 18 Years Old With COVID-19

NCT04431453
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 18 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 17, 2026, 5:27 AM EDT
Terminated Phase 3 Interventional Results available

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780541
View directory record Official record
Conditions
COVID-19
Interventions
PF-07304814, Placebo, Remdesivir
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Chula Vista, California • Los Angeles, California • Mather, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

NCT03719586
View directory record Official record
Conditions
Ebola Virus
Interventions
ZMapp, Remdesivir, MAb114, REGN-EB3
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 99 Years
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780281
View directory record Official record
Conditions
COVID-19
Interventions
VIR-7831, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 17, 2026, 5:27 AM EDT
Withdrawn Phase 3 Interventional

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

NCT04675086
View directory record Official record
Conditions
Covid19, Pneumonia, Viral
Interventions
alpha1-proteinase inhibitor, Antiviral Agents
Drug
Lead sponsor
Blessing Corporate Services, Inc
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Hannibal, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 17, 2026, 5:27 AM EDT
Recruiting No phase listed Observational

COVID-19 International Drug Pregnancy Registry

NCT05013632
View directory record Official record
Conditions
Covid19
Interventions
Antiviral Agents, Monoclonal antibody
Drug
Lead sponsor
Pregistry
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 17, 2026, 5:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health

NCT05553743
View directory record Official record
Conditions
Breastfeeding, COVID-19 Infection, COVID-19 Vaccine, Remdesivir, Antibiotics
Interventions
COVID-19 Exposure, Antibiotic
Biological · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2040
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib, Dexamethasone, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
61
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of Orally Administered GS-441524 for COVID-19

NCT04859244
View directory record Official record
Conditions
COVID-19
Interventions
GS-441524
Drug
Lead sponsor
Copycat Sciences LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 17, 2026, 5:27 AM EDT
Not listed No phase listed Observational

Risk Stratification of COVID-19 Using Urine Biomarkers

NCT04681040
View directory record Official record
Conditions
Covid19, Urine, Biomarker, Acute Respiratory Failure With Hypoxia
Interventions
Not listed
Lead sponsor
National Center for Global Health and Medicine, Japan
Government
Eligibility
20 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

NCT04292730
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
106
States / cities
Anaheim, California • Berkeley, California • Burlingame, California + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475
View directory record Official record
Conditions
COVID-19
Interventions
Interferon beta-1a, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
55
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

NCT04401579
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Baricitinib
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 17, 2026, 5:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 5:27 AM EDT
Completed Phase 2 Interventional

Phase 2a MIB-626 vs. Placebo COVID-19

NCT05038488
View directory record Official record
Conditions
Covid19, Stage 1 Acute Kidney Injury
Interventions
MIB-626, Placebo, Home Treatment
Drug · Other
Lead sponsor
Metro International Biotech, LLC
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 17, 2026, 5:27 AM EDT